• Welcome, Guest. Please login or register.
    December 10, 2018, 11:42:29 PM

  • Login with username, password and session length

Sajid's dove

Tell everyone they can now find this site by typing this into their browser:

thalpal.com

Click to visit us on Facebook


If you have any problems registering or signing in, please send an email to: andy@thalpal.com
Please do not send questions about thalassemia to this address.


Administrators
Andy
Danielle

Thalassemia Patients and Friends and thalpal © A. Battaglia 2018





54854 Posts in 5821 Topics by 6069 Members
Latest Member: Revia

This is Thalassemia Patients and Friends,
dedicated to its founder,
Lisa Cammilleri.
(1970-2004)
« previous next »
Pages: 1 Go Down Print
Author Topic: Nigella sativa  (Read 192 times)
ironjustice
Junior Member
***
Offline Offline

Posts: 128


« on: November 18, 2018, 04:19:16 PM »

Nigella sativa improves anemia, enhances immunity and relieves iron overload-induced oxidative stress as a novel promising treatment in children having beta-thalassemia major

Abstract
Introduction
Thalassemias are treated by regular blood transfusions and iron chelation therapy. Iron overload-induced oxidative stress helps the pathogenesis of thalassemia-induced anemia, atherogenesis, immune suppression and tissue damage. Nigella sativa (NS) is a safe medicinal plant that has exhibited immune stimulant, antioxidant and tissue-protective effects that may benefit thalassemic patients. It is widely used in Arabic prophetic medicine

Patients and methods
25 blood transfusion-dependent children having homozygous β-thalassmia major (11 Males and 14 females ranging from 6 to 18 years) received oral NS powder (2 g/day added to foods or drinks) for 3 consecutive months. Investigations carried out for all children included evaluating: complete blood count, serum ferrtin, T cell subsets determination (CD4 and CD8), malondialdehyde (MDA) level and total antioxidant capacity (TAC).

Results
NS significantly increased blood hemoglobin (from 7.50 ± 0.22 to 9.48 ± 0.6 g/dl) (p < 0.001), WBCs count (from 9683.33 ± 284.65 to 12070 ± 89 cells/cc) (p < 0.001) and neutrophils (from 3243.92 ± 168.81 to 4868.23 ± 387.92 cells/cc) (p < 0.001). NS enhanced cell-mediated immunity significantly via increasing CD4 counts (from 1319.88 ± 74.56 to 2007.64 ± 90.34 cells/ µl) (p < 0.001) and CD8 counts (from 727.09 ± 42.81 to 1145.31 ± 77.58 cells/µl) (p < 0.001) after NS treatment. Blood platelets and serum ferritin did not change significantly. However, iron overload-induced oxidative stress significantly decreased e.g. MDA significantly decreased (from 21.624 ± 0.31 to 14.864 ± 0.50 nmol/L) (p < 0.001) while TAC significantly increased (from 3.93 ± 0.11 to 7.69 ± 0.14 mmol/L) (p < 0.001) after NS treatment.

Conclusion
NS decreased iron overload-induced oxidative stress and hemolytic anemia. NS is a promising treatment for thalassemia to potentiate therapeutic effects and alleviate side effects of iron chelation therapy. Limitations to this study included the small number of patients and the relatively short post treatment follow-up time. Future research regarding the use of NS for the treatment of thalassemia is highly recommended

This clinical trial was registered in: ClinicalTrials.gov. Trial ID: NCT02816957

https://www.sciencedirect.com/science/article/pii/S2210803318300563?dgcid=rss_sd_all
Logged
Andy Battaglia
Administrator
Supreme Member
*****
Offline Offline

Location: In my heart, Maldives

Gender: Male
Posts: 8499


Will thal rule you or will you rule thal?


« Reply #1 on: November 29, 2018, 03:24:26 PM »

Possibly the most important herb on earth.
Logged

Andy

All we are saying is give thals a chance.
Pages: 1 Go Up Print 
« previous next »
Jump to:  

Powered by MySQL Powered by PHP Powered by SMF 1.1.21 | SMF © 2015, Simple Machines Valid XHTML 1.0! Valid CSS!